The content discusses a breakthrough blood test developed by Roche, in partnership with Amgen, that measures lipoprotein(a) [Lp(a)] levels. Lp(a) is a type of lipoprotein that is genetically inherited, and elevated levels have been associated with an increased risk of heart disease, stroke, and other blood vessel diseases.
The Tina-quant Lp(a) RxDx assay has received breakthrough device designation from the FDA, which is intended to expedite the development and review of devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. If approved, the test will be available on select Roche cobas platforms.
Elevated Lp(a) levels are prevalent in about 1 in 5 people worldwide, particularly among women and individuals of African descent. While low-density-lipoprotein (LDL) cholesterol is the primary risk factor for heart disease, Lp(a) has a higher atherogenic risk per particle compared to LDL cholesterol.
Currently, there are no approved pharmacologic therapies to lower Lp(a) levels in the United States, but several promising treatments, such as short interfering RNA (siRNA) agents, are in development to target the LPA gene and reduce Lp(a) synthesis.
他の言語に翻訳
原文コンテンツから
www.medscape.com
抽出されたキーインサイト
by Megan Brooks 場所 www.medscape.com 05-29-2024
https://www.medscape.com/viewarticle/roche-blood-test-lp-designated-breakthrough-device-2024a1000a3k深掘り質問